Activity Dates: 04/27/2020 - 04/27/2023
This course is designed for pharmacists, nurse practitioners or other health care professionals involved in the comprehensive medication management of psychiatric and/or neurological patients.
You will proceed through the following steps to satisfactorily complete this course:
Upon successful completion, ACPE credit is reported within 24 hours to CPE Monitor although transcripts can be retrieved by participants online in their ACPE Transcript.
AAPP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access AAPP course materials online, you will need:
AAPP web sites no longer fully support Microsoft Internet Explorer or Windows 8.1 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Royce Lee, MD
View biographical informationThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
2020 CPNP Recertification Editorial Board Disclosures
Mary C. Borovicka, PharmD, BCPP, BCPS Associate Professor University of Toledo College of Pharmacy and Pharmaceutical Sciences Cleveland, OH External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Ohio Pharmacists Association - LAI and naltrexone training inj |
Beth DeJongh, PharmD, BCPP, BCPS Recertification Editorial Board Vice Chair Pharmacist Concordia University Wisconsin Mequon, WI No Relevant Financial Relationships to Disclose |
Sara E. Dugan, PharmD, BCPP, BCPS Associate Professor Northeast Ohio Medical University College of Pharmacy and Medicine Rootstown, OH Educational Grants, Research Grants or Contracts: Ohio Colleges of Medicine Government Research Center, Northeast Ohio Medical University College of Medicine Department of Psychiatry |
Clayton D. English, PharmD, BCPS, BCPP, BCGP |
Michelle L. Geier, PharmD, BCPP Psychiatric Clinical Pharmacist Supervisor San Francisco Department of Public Health San Francisco, CA No Relevant Financial Relationships to Disclose |
Rebecca Graham, PharmD, BCPP Clinical Pharmacy Specialist - Mental Health Corporal Michael J. Crescenz VA Medical Center in Philadelphia Philadelphia, PA No Relevant Financial Relationships to Disclose |
Courtney A. Iuppa, PharmD, BCPP Clinical Pharmacy Manager & Residency Program Director Center for Behavioral Medicine Kansas City, MO No Relevant Financial Relationships to Disclose |
Rex S. Lott, PharmD, BCPP BCPP Program Director Professor Emeritus of Pharmacy Practice Idaho State University - College of Pharmacy Meridian, ID No Relevant Financial Relationships to Disclose |
Monica Mathys, PharmD, BCPP, BCGP Associate Professor Texas Tech University School of Pharmacy Dallas, TX Non-Financial Interests: CPNP Foundation Board member |
Sarah T. Melton, PharmD, BCPP, BCACP, FASCP Recertification Editorial Board Chair Professor of Pharmacy Practice Gatton College of Pharmacy Johnson City, TN Non-Financial Interests: One Care of Southwest Virginia |
Thea R. Moore, PharmD, BCPP Associate Professor University of South Florida Tampa, FL Educational Grants, Research Grants or Contracts: Agency for Health Care Administration |
Jessica L. Mulhollan, PharmD, BCPP Psychiatric Clinical Pharmacy Specialist Cleveland Clinic Marymount Hospital Garfield Heights, OH No Relevant Financial Relationships to Disclose |
Sandra Mullen, PharmD, BCPP Clinical Pharmacy Specialist - Psychiatry VCU Health Systems Richmond, VA Non-Financial Interests: Lambda Kappa Sigma Grand Council (Executive Board) |
Stephanie Nichols, PharmD, BCPP, BCPS, FCCP Associate Professor of Pharmacy Practice Husson University Saco, ME Non-Financial Interests: Member of the New England Comparative Effectiveness Public Advisory Committee of the Institute for Clinical and Economic Review, Maine Independent Clinical Information Service Academic Detailing Advisory Committee |
Sarah J. Popish, PharmD, BCPP Academic Educator Department of Veterans Affairs Vallejo, CA No Relevant Financial Relationships to Disclose |
Megan M. Sarashinsky, PharmD, BCPP Clinical Pharmacy Specialist CJW Medical Center Richmond, VA No Relevant Financial Relationships to Disclose |
Andrea Winterswyk, PharmD, BCPS, BCPP Mental Health Clinical Pharmacy Specialist Boise Veterans Affairs Medical Center Boise, ID No Relevant Financial Relationships to Disclose |
Kara R. Wong, PharmD, BCPP Clinical Pharmacy Specialist, Mental Health; PGY2 Psychiatric Pharmacy Residency Program Director Minneapolis VA Health Care System Minneapolis, MN No Relevant Financial Relationships to Disclose |
All relevant relationships have been mitigated.
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: aripiprazole, brexpiprazole, carbamazepine, citalopram, clozapine, dexmedetomidine, droperidol, haloperidol, ketamine, midazolam, olanzapine, promethazine, propranolol, quetiapine, risperidone, and valproate
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.